VINS Visits AtaGenix Wuhan HQ for Biopharma Partnership

On June 25, 2025, a delegation from VINS Bioproducts Limited (hereinafter “VINS”), a well-known Indian biopharmaceutical company, visited the Wuhan headquarters of AtaGenix (Pujian Biotech) for exchanges and collaboration. The visit aimed to further strengthen strategic cooperation in vaccine raw materials, biological antibodies, and CRO custom services, jointly promoting global public health and innovative drug R&D.

Fig.1. Group photo of the VINS delegation and the AtaGenix team

The VINS delegation was composed of senior leaders from R&D and international business. AtaGenix co-founder Mr. Fubo Qin, General Manager Mr. Liang Lu, and other core team members joined the reception and discussions.

During the tour, the VINS team visited AtaGenix’s R&D laboratories, quality management center, and antibody preparation platform. They gained in-depth understanding of the company’s core technologies and project outcomes in single B-cell antibody screening, affinity maturation engineering, eukaryotic protein expression, and vaccine adjuvant optimization. The delegation highly recognized AtaGenix’s technical depth and delivery capability in antibody engineering and customized services.

At the roundtable, Mr. Fubo Qin introduced AtaGenix’s R&D layout and global collaboration network in infectious diseases, tumor immunology, and anti-toxin antibodies, emphasizing the company’s customer-centric approach to providing flexible and efficient customized R&D solutions. General Manager Mr. Liang Lu added: “We value the cooperation potential with VINS. The two sides are highly complementary in vaccine immunogen design and antibody drug development, and we look forward to deep synergy in international project linkage and translational outcomes.”

The VINS team also shared its product portfolio in antivenom serum, immunoglobulin preparations, and innovative vaccine platforms, along with its experience in overseas market expansion. They expressed a strong willingness to work with AtaGenix on joint R&D, technology transfer, and market co-development across multiple programs.

This visit not only deepened mutual understanding and trust between AtaGenix and VINS, but also laid a solid foundation for subsequent co-development and commercialization. Looking ahead, AtaGenix will continue to uphold its mission of “connecting global biopharmaceutical innovation through technology,” joining hands with partners worldwide to promote high-quality development of the biopharma industry and contribute to human health.

AtaGenix— Company Profile

AtaGenix (Pujian Biotech) is a high-tech biotechnology company headquartered in Wuhan, China, specializing in antibody engineering, protein expression, and vaccine-related services. The company operates advanced platforms for single B-cell antibody screening, affinity maturation engineering, and eukaryotic protein expression systems, dedicated to delivering high-quality CRO customization for global clients. With extensive R&D across infectious diseases, tumor immunology, and in-vivo functional antibodies, AtaGenix has built collaborative networks with research institutes and enterprises worldwide to drive biopharmaceutical innovation through technological advancement.

VINS Bioproducts Limited — Company Profile

Founded in 1997 and headquartered in Hyderabad, India, VINS Bioproducts Limited is a biopharmaceutical company specializing in the production of biologicals such as antivenom serum, anti-rabies serum, tetanus antitoxin, scorpion antitoxin, and diphtheria antitoxin. VINS operates automated production facilities that meet international standards and manages a 150-acre equine farm. Its products are exported to more than 110 countries across Asia, Africa, the Middle East, Europe, Australia, and the Americas. In collaboration with global organizations including the WHO and UNICEF, VINS is committed to providing high-quality biopharmaceutical solutions for global public health.